title: Transient reduction in serum HDL-cholesterol following medroxyprogesterone acetate and testosterone cypionate administration to healthy men.
abstract: Serum lipids were examined in thirty normal male volunteers who had received depo-medroxyprogesterone acetate (DMPA) and testosterone cypionate (TC) in a male contraceptive trial. Progestagens have been implicated in the changes in serum lipids observed in women using oral contraceptives and this has led to concern about cardiovascular health risks associated with the long-term use of some of these preparations. The following study was done to determine if similar effects occur in men. The men in this study were divided into three DMPA dose groups (50, 100, 200 mg/month) and received intramuscular injections for six months; all men received 250 mg/month TC. There was no significant change in serum high density lipoprotein-cholesterol (HDL-C) levels during the six months of drug administration when compared to levels in the control period. However, there was a marked decrease in HDL-C during the first three months after discontinuation of the drugs (p less than 0.02). This observed change was consistent in each of the three DMPA dose groups but no dose relationship was observed. There was no statistically significant change in serum concentrations of total cholesterol, low density lipoprotein-cholesterol, triglycerides or insulin in any period of the experiment. Serum testosterone (T), estradiol, and sex hormone binding globulin (SHBG), luteinizing hormone (LH), and follicle stimulating hormone (FSH) concentrations were all significantly depressed during the drug administration period. A progestagen dose relationship was observed only for the decrease in serum testosterone and LH concentrations. Serum T and SHBG levels were still significantly reduced at 4-6 months after cessation of the drug administration. These findings demonstrate that DMPA can cause a reduction in serum HDL-C levels. It is suggested that HDL-C concentrations fell only following DMPA withdrawal as a consequence of steroid hormone changes specific to this period.
authors.forename: K E
authors.initials: KE
authors.lastname: Friedl
authors.forename: S R
authors.initials: SR
authors.lastname: Plymate
authors.forename: C A
authors.initials: CA
authors.lastname: Paulsen
mesh_terms: D019326:17-alpha-Hydroxyprogesterone; D000328:Adult; D008076:Cholesterol, HDL / Q000097:blood*; D003272:Contraceptive Agents, Male; D004958:Estradiol / Q000097:blood; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D006908:Hydroxyprogesterones / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000494:pharmacology; D017258:Medroxyprogesterone Acetate; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013739:Testosterone / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology
chemical_list: D008076:Cholesterol, HDL; D003272:Contraceptive Agents, Male; D006908:Hydroxyprogesterones; D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; D004958:Estradiol; D019326:17-alpha-Hydroxyprogesterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; C016131:testosterone 17 beta-cypionate